Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2026-01-08 00:00:00 ET · period of report 2026-01-06 · accession 0002081169-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | 2026-01-06 | ARWR | Apel Daniel Joseph | CFO | A - Grant | $0.00 | +75.0K | 176.2K | +74% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-06 | A | A | 75,000 | $0.00 | 176,200 | D | — | — | (F1) Represents shares underlying restricted stock units which will vest in four equal annual installments. (F2) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |